Having trouble accessing articles? Reset your cache.

Arbaclofen: Phase II data

In the per protocol (PP) population (n=54) of a double-blind, crossover, U.S. Phase II trial, STX209 missed the primary endpoint of significantly improving irritability subscale scores on the ABC-I from baseline to week 4 vs.

Read the full 350 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE